Maravai Lifesciences Holdings (MRVI) Cash from Investing Activities (2020 - 2026)

Maravai Lifesciences Holdings' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$4.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 80.82% year-over-year to -$4.4 million in Q1 2026; TTM through Mar 2026 was -$12.7 million, a 70.57% increase from a year earlier, with the FY2025 full-year figure at -$31.4 million, down 29.15% from the prior year.
• Cash from Investing Activities eased to -$4.4 million in Q1 2026 per MRVI's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$1.7 million in Q2 2022 and bottomed at -$241.6 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$6.2 million (2024), against an average of -$26.5 million.
• Across the five-year window, Cash from Investing Activities sank 8577.59% in 2022 and surged 93.91% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$18.5 million in 2022, then surged by 30.33% to -$12.9 million in 2023, then surged by 61.78% to -$4.9 million in 2024, then soared by 57.13% to -$2.1 million in 2025, then tumbled by 109.89% to -$4.4 million in 2026.
• Per Business Quant, the three latest MRVI Cash from Investing Activities figures stand at -$4.4 million (Q1 2026), -$2.1 million (Q4 2025), and -$2.9 million (Q3 2025).